- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: INCSHR1210 | SHR-1210
camrelizumab is an approved drug (China (2019))
Compound class: Antibody
Comment: Camrelizumab is a fully human anti-programmed cell death 1 (PD-1) monoclonal antibody being developed as an immuno-oncology therapeutic.
Clinical efficacy of camrelizumab plus thymosin in patients with COVID-19 will be evaluated in clinical trial NCT04268537.
|Approved drug?||Yes (China (2019))|
|International Nonproprietary Names|
|INCSHR1210 | SHR-1210|
|GtoPdb PubChem SID||354702231|
|Search PubMed clinical trials||camrelizumab|
|Search PubMed titles||camrelizumab|
|Search PubMed titles/abstracts||camrelizumab|